If there’s a silver lining to the COVID pandemic, it’s that we advanced mRNA technology to develop the next generation of vaccines, therapeutics, and cures.
The numbers: Over 670 million mRNA vaccines have been delivered in the U.S. in just two years—which seems like “an astonishingly fast turnaround for any new drug,” says MIT Technology Review.
But this “follows years of research on the core technology. Scientists and companies have been working on mRNA-based treatments and vaccines for decades,” continues MIT.
Now, we’re seeing breakthroughs, including…
What’s next: Moderna just announced a new partnership with CytomX Therapeutics to develop mRNA therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases—read more.
More Health News:
Bloomberg: CDC will roll out sweeping changes to handle emergencies
“The CDC director will require all employees to be ready to deploy to combat national health crises, marking a drastic shift from a fragmented volunteer system that hampered its COVID-19 response, according to Walensky and other top CDC leadership who previewed a series of measures the agency will implement to better prepare for emergencies. Others include elimination of management layers, elevation of laboratory sciences, and the possible formation of a CDC unit dedicated to coronaviruses within its immunizations and respiratory disease arm.”
Eisai: FDA approves LEQEMBI™ under the Accelerated Approval pathway for the treatment of Alzheimer’s disease
“The approval is based on Phase 2 data that demonstrated that LEQEMBI reduced the accumulation of Aβ plaque in the brain,” says the company’s statement. “Eisai has made great efforts to understand the reality of the challenges and concerns facing patients and their families who are living in the various stages of Alzheimer's disease, and we are incredibly pleased to offer LEQEMBI as a new treatment option to help with the tremendous unmet needs of this community," said Eisai CEO Haruo Naito.
